vs
IBEX Ltd（IBEX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是IBEX Ltd的1.3倍（$207.3M vs $164.2M），IBEX Ltd净利率更高（7.4% vs -62.0%，领先69.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 16.7%），IBEX Ltd自由现金流更多（$-5.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 13.8%）
IBEX 35是西班牙主要交易所马德里证券交易所的基准股票指数，该指数始创于1992年，由西班牙证券市场集团BME旗下的交易所公司负责计算与管理。它以市值加权编制，涵盖马德里证券交易所流动性最高的35只西班牙股票，每年进行两次成分股调整。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
IBEX vs RARE — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.2M | $207.3M |
| 净利润 | $12.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 9.3% | -54.7% |
| 净利率 | 7.4% | -62.0% |
| 营收同比 | 16.7% | 25.9% |
| 净利润同比 | 31.8% | 3.5% |
| 每股收益（稀释后） | $0.83 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $164.2M | $207.3M | ||
| Q3 25 | $151.2M | $159.9M | ||
| Q2 25 | $147.1M | $166.5M | ||
| Q1 25 | $140.7M | $139.3M | ||
| Q4 24 | $140.7M | $164.6M | ||
| Q3 24 | $129.7M | $139.5M | ||
| Q2 24 | $124.5M | $147.0M | ||
| Q1 24 | $126.8M | $108.8M |
| Q4 25 | $12.2M | $-128.6M | ||
| Q3 25 | $12.0M | $-180.4M | ||
| Q2 25 | $9.6M | $-115.0M | ||
| Q1 25 | $10.5M | $-151.1M | ||
| Q4 24 | $9.3M | $-133.2M | ||
| Q3 24 | $7.5M | $-133.5M | ||
| Q2 24 | $9.8M | $-131.6M | ||
| Q1 24 | $10.3M | $-170.7M |
| Q4 25 | 9.3% | -54.7% | ||
| Q3 25 | 9.1% | -106.9% | ||
| Q2 25 | 8.3% | -64.8% | ||
| Q1 25 | 9.5% | -102.6% | ||
| Q4 24 | 8.5% | -74.3% | ||
| Q3 24 | 7.0% | -94.6% | ||
| Q2 24 | 10.3% | -79.1% | ||
| Q1 24 | 8.9% | -151.9% |
| Q4 25 | 7.4% | -62.0% | ||
| Q3 25 | 8.0% | -112.8% | ||
| Q2 25 | 6.5% | -69.0% | ||
| Q1 25 | 7.4% | -108.5% | ||
| Q4 24 | 6.6% | -80.9% | ||
| Q3 24 | 5.8% | -95.7% | ||
| Q2 24 | 7.9% | -89.5% | ||
| Q1 24 | 8.1% | -156.8% |
| Q4 25 | $0.83 | $-1.28 | ||
| Q3 25 | $0.82 | $-1.81 | ||
| Q2 25 | $0.63 | $-1.17 | ||
| Q1 25 | $0.73 | $-1.57 | ||
| Q4 24 | $0.57 | $-1.34 | ||
| Q3 24 | $0.43 | $-1.40 | ||
| Q2 24 | $0.55 | $-1.52 | ||
| Q1 24 | $0.57 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $421.0M |
| 总债务越低越好 | $594.0K | — |
| 股东权益账面价值 | $154.5M | $-80.0M |
| 总资产 | $295.8M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
| Q4 25 | $15.5M | $421.0M | ||
| Q3 25 | $22.7M | $202.5M | ||
| Q2 25 | $15.3M | $176.3M | ||
| Q1 25 | $13.0M | $127.1M | ||
| Q4 24 | $20.2M | $174.0M | ||
| Q3 24 | $62.3M | $150.6M | ||
| Q2 24 | $62.7M | $480.7M | ||
| Q1 24 | $50.7M | $112.3M |
| Q4 25 | $594.0K | — | ||
| Q3 25 | $726.0K | — | ||
| Q2 25 | $796.0K | — | ||
| Q1 25 | $735.0K | — | ||
| Q4 24 | $695.0K | — | ||
| Q3 24 | $802.0K | — | ||
| Q2 24 | $867.0K | — | ||
| Q1 24 | $820.0K | — |
| Q4 25 | $154.5M | $-80.0M | ||
| Q3 25 | $143.6M | $9.2M | ||
| Q2 25 | $134.3M | $151.3M | ||
| Q1 25 | $124.2M | $144.2M | ||
| Q4 24 | $108.9M | $255.0M | ||
| Q3 24 | $171.1M | $346.8M | ||
| Q2 24 | $165.8M | $432.4M | ||
| Q1 24 | $159.3M | $140.3M |
| Q4 25 | $295.8M | $1.5B | ||
| Q3 25 | $283.9M | $1.2B | ||
| Q2 25 | $273.2M | $1.3B | ||
| Q1 25 | $274.7M | $1.3B | ||
| Q4 24 | $272.5M | $1.5B | ||
| Q3 24 | $306.3M | $1.5B | ||
| Q2 24 | $293.9M | $1.6B | ||
| Q1 24 | $289.6M | $1.3B |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-5.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | -3.1% | -48.6% |
| 资本支出强度资本支出/营收 | 7.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.54× | — |
| 过去12个月自由现金流最近4个季度 | $29.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $6.6M | $-99.8M | ||
| Q3 25 | $15.7M | $-91.4M | ||
| Q2 25 | $27.9M | $-108.3M | ||
| Q1 25 | $8.8M | $-166.5M | ||
| Q4 24 | $1.1M | $-79.3M | ||
| Q3 24 | $7.8M | $-67.0M | ||
| Q2 24 | $17.4M | $-77.0M | ||
| Q1 24 | $11.4M | $-190.7M |
| Q4 25 | $-5.1M | $-100.8M | ||
| Q3 25 | $8.0M | $-92.7M | ||
| Q2 25 | $22.8M | $-110.7M | ||
| Q1 25 | $3.6M | $-167.8M | ||
| Q4 24 | $-3.2M | $-79.5M | ||
| Q3 24 | $4.1M | $-68.6M | ||
| Q2 24 | $15.2M | $-79.0M | ||
| Q1 24 | $9.7M | $-193.9M |
| Q4 25 | -3.1% | -48.6% | ||
| Q3 25 | 5.3% | -58.0% | ||
| Q2 25 | 15.5% | -66.5% | ||
| Q1 25 | 2.5% | -120.5% | ||
| Q4 24 | -2.3% | -48.3% | ||
| Q3 24 | 3.2% | -49.2% | ||
| Q2 24 | 12.2% | -53.7% | ||
| Q1 24 | 7.7% | -178.2% |
| Q4 25 | 7.1% | 0.5% | ||
| Q3 25 | 5.1% | 0.8% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 3.7% | 1.0% | ||
| Q4 24 | 3.1% | 0.1% | ||
| Q3 24 | 2.8% | 1.2% | ||
| Q2 24 | 1.8% | 1.4% | ||
| Q1 24 | 1.3% | 3.0% |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 1.30× | — | ||
| Q2 25 | 2.91× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.77× | — | ||
| Q1 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBEX
| Transferred Over Time | $147.1M | 90% |
| Transferred At Point In Time | $17.1M | 10% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
